0000000000385590

AUTHOR

François Vergez

0000-0002-0063-4404

showing 2 related works from this author

Assessment of tumor-infiltrating TCRV γ 9V δ 2 γδ lymphocyte abundance by deconvolution of human cancers microarrays

2017

Most human blood γδ cells are cytolytic TCRVγ9Vδ2+lymphocytes with antitumor activity. They are currently investigated in several clinical trials of cancer immunotherapy but so far, their tumor infiltration has not been systematically explored across human cancers. Novel algorithms allowing the deconvolution of bulk tumor transcriptomes to find the relative proportions of infiltrating leucocytes, such as CIBERSORT, should be appropriate for this aim but in practice they fail to accurately recognize γδ T lymphocytes. Here, by implementing machine learning from microarray data, we first improved the computational identification of blood-derived TCRVγ9Vδ2+γδ lymphocytes and then appl…

0301 basic medicineAcute promyelocytic leukemia[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematologylcsh:Immunologic diseases. AllergyArtificial intelligenceMicroarrayLymphocytemedicine.medical_treatmentImmunologyInflammationchemical and pharmacologic phenomenagamma delta lymphocyteBiologydeconvolutionlcsh:RC254-28203 medical and health sciences0302 clinical medicineCancer immunotherapymedicineImmunology and AllergycancerOriginal ResearchTumor-infiltrating lymphocytesAntigen processingMyeloid leukemiahemic and immune systems[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematologydata miningmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good health030104 developmental biologymedicine.anatomical_structuremachine learningOncology030220 oncology & carcinogenesisImmunologymedicine.symptomlcsh:RC581-607microarraytranscriptome
researchProduct

Longitudinal Immunogenomic Profiling of Tumor and Immune Cells for Minimally-Invasive Monitoring of Smoldering Multiple Myeloma (SMM): The Immunocell…

2020

Background: Although great strides were made in the management of MM, our best chances to eradicate this malignancy may lie in preventing its progression.Most current models to predict risk of transformation in SMM are commonly established at diagnosis and not reevaluated over time, because some parameters such as tumor burden or genetic abnormalities require invasive bone marrow (BM) aspirates. It could be hypothesized that periodic monitoring of tumor biomarkers is needed to improve risk-stratification of SMM patients, and so would be new minimally-invasive methods that can replace those performed in BM samples. Such methods should also monitor immune profiles, to identify patients with s…

business.industryeducationImmunologyCell BiologyHematologymedicine.diseaseBiochemistryImmune systemCancer researchMedicineProfiling (information science)businesshealth care economics and organizationsMultiple myelomaBlood
researchProduct